Cidara Therapeutics’ business outlook improved substantially on June 23 after releasing pre-market Phase IIb data for its non-vaccine seasonal influenza prevention agent showing better prophylaxis capabilities than usually seen with flu shots. The San Diego firm said on a same-day call that it hopes to convene end-of-Phase II talks with the US Food and Drug Administration soon to plan a pivotal study.
Key Takeaways
- Cidara unveiled Phase IIb data for its non-vaccine flu prevention agent CD388 showing statistical significance for preventive efficacy at three tested doses.
The positive topline Phase IIb data for CD388, a drug-Fc conjugate (DFC), provide validation for Cidara’s change of course in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?